Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
- Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms
- Portfolio will be sold at zero-profit to governments in up to 791?eligible countries during the pandemic and until a vaccine or curative treatment is available
- Early access to treatment for managing? COVID-19 symptoms is critical to preventing healthcare system overload
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comPeter Zuest | Katrina Lucking |
Novartis External Communications | Novartis Global Health Communications |
+41 79 899 9812 (mobile) | +41 79 484 7625 (mobile) |
peter.zuest@novartis.com | katrina.lucking@novartis.com |
Eric Althoff | |
Novartis US External Communications | |
+1 646 438 4335 | |
Eric.althoff@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |